Subjective Versus Objective Weight Gain during Acute Treatment with Second-Generation Antipsychotics in Schizophrenia and Bipolar Disorder

Journal of Clinical Psychopharmacology

Volumn 36, Issue 6, 2016, Pages 637-642

  Gao, Keming ^a   Fang, Fang ^b   Wang, Zuowei ^b   Calabrese, Joseph R ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Mental Health Centre of Hongkou District   (China)

Author keywords

antipsychotics; bipolar disorder; objective weight gain; schizophrenia; subjective weight gain

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BLONANSERIN; BREXPIPRAZOLE; CARIPRAZINE; CARPIPRAMINE; CLOZAPINE; ILOPERIDONE; LURASIDONE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; EMERGENCY CARE; HUMAN; MENTAL PATIENT; META ANALYSIS (TOPIC); MONOTHERAPY; NUMBERS NEEDED TO TREAT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SCHIZOPHRENIA; SELF REPORT; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN; COMPARATIVE STUDY; DRUG EFFECTS; META ANALYSIS;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; SCHIZOPHRENIA; SELF REPORT; WEIGHT GAIN;

EID: 84991449268     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000596     Document Type: Article

References (37)

1. Manios Y, Moschonis G, Karatzi K, et al. Large proportions of overweight and obese children, aswell as their parents, underestimate children's weight status across Europe. The ENERGY (EuropeaN Energy balance Research to prevent excessive weight Gain among Youth) project. Public Health Nutr. 2015;18:2183-2190.
2. Pérez A, Gabriel K, Nehme EK, et al. Measuring the bias, precision, accuracy, and validity of self-reported height and weight in assessing overweight and obesity status among adolescents using a surveillance system. Int J Behav Nutr Phys Act. 2015;12(Suppl 1):S2.
3. Clarke P, Sastry N, Duffy D, et al. Accuracy of self-reported versus measured weight over adolescence and young adulthood: findings fromthe national longitudinal study of adolescent health, 1996-2008. Am J Epidemiol. 2014;180:153-159.
4. Yang K, Turk MT, Allison VL, et al. Body mass index self-perception and weight management behaviors during late adolescence. J Sch Health. 2014; 84:654-660.
5. De Vriendt T, Huybrechts I, Ottevære C, et al. Validity of self-reported weight and height of adolescents, its impact on classification into BMI-categories and the association with weighing behaviour. Int J Environ Res Public Health. 2009;6:2696-2711.
6. Pursey K, Burrows TL, Stanwell P, et al. How accurate is web-based self-reported height, weight, and body mass index in young adults? J Med Internet Res. 2014;16:e4.
7. Lin CJ, DeRoo LA, Jacobs SR, et al. Accuracy and reliability of self-reported weight and height in the Sister Study. Public Health Nutr. 2012;15:989-999.
8. Wen M, Kowaleski-Jones L. Sex and ethnic differences in validity of self-reported adult height, weight and bodymass index. Ethn Dis. 2012;22: 72-78.
9. Vailas LI, Nitzke SA. Self-reported versus measured weight and height in an older adult meal program population. J Gerontol A Biol Sci Med Sci. 1998;53:M481-M483.
10. Shields M, Gorber SC, Tremblay MS. Effects of measurement on obesity and morbidity. Health Rep. 2008;19:77-84.
11. Wang F, Xiang YT, Ungvari GS, et al. Prevalence of overweight in schizophrenia patients in Asia: findings of the research on Asian psychotropic prescription patterns (REAP) study. Int J Clin Pharmacol Ther. 2016;54:450-455.
12. Chwastiak LA, Rosenheck RA, Kazis LE. Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans. Psychosomatics. 2011;52:230-236.
13. Mitchell AJ, Vancampfort D, De Herdt A, et al. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39:295-305.
14. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry. 2001;46:549-555.
15. Dickerson FB, Brown CH, Kreyenbuhl JA, et al. Obesity among individuals with serious mental illness. Acta Psychiatr Scand. 2006;113: 306-313.
16. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63: 207-213.
17. Kemp DE, Sylvia LG, Calabrese JR, et al. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr Scand. 2014;129:24-34.
18. Goldstein BI, Liu SM, Schaffer A, et al. Obesity and the three-year longitudinal course of bipolar disorder. Bipolar Disord. 2013;15:284-293.
19. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51:274-280.
20. Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009;113: 49-55.
21. Leucht S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012; 5:CD008016.
22. Gao K, Kemp DE, Wu R, et al. Mood Stabilizers. In: Tasman A, Kay J, Lieberman JA, et al. eds. Psychiatry, Fourth Edition. Chichester UK: John Wiley & Sons, Ltd, 2015;2129-2153.
23. Tschoner A, Engl J, LaimerM, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61:1356-1370.
24. Reist C, Mintz J, Alberts L. Second-generation antipsychotic exposure and metabolic- related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007;27:46-51.
25. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008;28:203-209.
26. Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008;69:302-309.
27. Nekovarova T, Fajnerova I, Horacek J, et al. Bridging disparate symptoms of schizophrenia: a triple network dysfunction theory. Front Behav Neurosci. 2014;8:171.
28. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr Scand Suppl. 1999;395: 113-117.
29. Loh C, Meyer JM, Leckband SG. Accuracy of body image perception and preferred weight loss strategies in schizophrenia: a controlled pilot study. Acta Psychiatr Scand. 2008;117:127-132.
30. Ferri F, Frassinetti F, Mastrangelo F, et al. Bodily self and schizophrenia: the loss of implicit self-body knowledge. Conscious Cogn. 2012;21:1365-1374.
31. Moteshafi H, Zhornitsky S, Brunelle S, et al. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf. 2012;35:819-836.
32. Moteshafi H, Stip E. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opin Drug Saf. 2012;11:713-732.
33. Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011;72:1063-1071.
34. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:562-951.
35. Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011;72 (Suppl 1):19-23.
36. Fang F, Wang Z, Wu R, et al. Is There a "Weight Neutral" Second-Generation Antipsychotic for Bipolar Disorder? Expert Rev Neurother, in press.
37. Milano W, De Rosa M, Milano L, et al. Antipsychotic drugs opposite to metabolic risk: neurotransmitters, neurohormonal and pharmacogenetic mechanisms underlying with weight gain and metabolic syndrome. Open Neurol J. 2013;7:23-31.